Drug class

Hypoglycemics - Sulfonylureas and Related Non-Sulfonylureas

Hypoglycemics – sulfonylureas and related non-sulfonylureas (commonly termed meglitinides or glinides) is a therapeutic category of oral antidiabetic secretagogues. Read more about Hypoglycemics - Sulfonylureas and Related Non-Sulfonylureas

108 drugs in this class 50 manufacturers

Advertisement

Drugs in Hypoglycemics - Sulfonylureas and Related Non-Sulfonylureas

Showing 10–18 of 108 drugs

GLIPIZIDE

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
MYLAN INSTITUTI

NATEGLINIDE

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
AHP

GLIPIZIDE XL (glipizide)

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
GREENSTONE LLC.

GLYBURIDE

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
TEVA USA

GLYBURIDE

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
AUROBINDO PHARM

REPAGLINIDE

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
AUROBINDO PHARM

GLIMEPIRIDE

HYPOGLYCEMICS - SULFONYLUREAS AND RELATED NON-SULFONYLUREAS · TYPE 2 DIABETES MELLITUS
BLUEPOINT LABOR
Filter & compare in the drug finder → Opens the drug finder with Hypoglycemics - Sulfonylureas and Related Non-Sulfonylureas preselected. Add indication or manufacturer filters there.

About Hypoglycemics - Sulfonylureas and Related Non-Sulfonylureas.

Hypoglycemics – sulfonylureas and related non-sulfonylureas (commonly termed meglitinides or glinides) is a therapeutic category of oral antidiabetic secretagogues.

These agents function primarily by binding to sulfonylurea receptor subunits on ATP-sensitive potassium channels in pancreatic beta cells, triggering channel closure, membrane depolarization, and subsequent calcium-dependent insulin exocytosis.

While sulfonylureas provide prolonged insulin release, the non-sulfonylurea glinides exhibit a more rapid onset and shorter duration of action to target postprandial glucose surges.

Clinically, these agents are indicated as adjuncts to diet and exercise to improve glycemic control exclusively in adults with type 2 diabetes mellitus.